DECDURA - Trademark Details
Status: 606 - Abandoned - No Statement Of Use Filed
Image for trademark with serial number 87725497
Serial Number
87725497
Word Mark
DECDURA
Status
606 - Abandoned - No Statement Of Use Filed
Status Date
2022-01-31
Filing Date
2017-12-18
Mark Drawing
4000 - Standard character mark Typeset
Published for Opposition Date
2018-10-30
Attorney Name
Law Office Assigned Location Code
L70
Employee Name
KAJUBI, ELIZABETH N
Statements
Goods and Services
Medicated and pharmaceutical preparations, both prescription and over-the-counter, for use in connection with humans and animals, namely, for the treatment of central nervous system disorders, neurologic illnesses, and psychiatric illnesses; pharmaceutical preparations for the treatment of brain ischemia; pharmaceutical preparations for the treatment of brain ischemia, namely, post-stroke recovery, severe intracranial atherosclerosis, carotid endarterectomy, cardiac bypass, cerebral vasculitis, reversible cerebral vasoconstriction syndrome; pharmaceutical preparations for the treatment of brain and cord injuries; pharmaceutical preparations for the treatment of brain and cord injuries, namely, post-intracranial hemorrhage recovery, traumatic brain injury, spinal cord injury; pharmaceutical preparations for the treatment of neurodegenerative diseases; pharmaceutical preparations for the treatment of neurodegenerative diseases, namely, Alzheimer's disease (AD), Amyotrophic Lateral Sclerosis (ALS), Huntington's disease, Lewy body dementia, frontotemporal dementia, vascular dementia, Parkinson's disease, cognitive impairment of aging, progressive Multiple Sclerosis; pharmaceutical preparations for the treatment of optic and retinal neuropathies; pharmaceutical preparations for the treatment of optic and retinal neuropathies, namely, glaucoma, diabetic retinopathy, ischemic optic and retinal neuropathies; pharmaceutical preparations for the treatment of pain; pharmaceutical preparations for the treatment of pain, namely, opioid sparing analgesia, cancer pain, chronic neuropathic pain, peripheral neuropathy, low back pain in the nature of failed back surgery syndrome, radiculopathy in the nature of sciatica, diabetic peripheral neuropathy, post-herpetic neuralgia, chemotherapy induced neuropathy and other medication induced neuropathies, complex regional pain syndrome, fibromyalgia, chronic post-operative pain, cluster thoracotomy, phantom limb, stump neuroma; pharmaceutical preparations for the treatment of headache and facial pain, namely, headache, migraine, chronic daily headache, cluster headache, trigeminal neuralgia; pharmaceutical preparations for symptomatic treatments of degenerative diseases; pharmaceutical preparations for symptomatic treatments of degenerative diseases, namely, breath holding in Rett syndrome, dystonias, dysphagia, gait abnormalities, bulbar function in ALS, pseudobulbar affect, levodopa-induced dyskinesias in Parkinson's disease, agitation in AD, disinhibition in dementia; pharmaceutical preparations for the treatment of epilepsy; pharmaceutical preparations for the treatment of epilepsy, namely, precision medicine - adjuvant for genetic epilepsy due to NMDA receptor mutations with hyperactivation; pharmaceutical preparations for the treatment of neuropsychiatric disorders; pharmaceutical preparations for the treatment of neuropsychiatric disorders, namely, treatment resistant depression, Post Traumatic Stress Disorder (PTSD) in the nature of hyperarousal, substance abuse disorders, addiction disorders, Obsessive Compulsive Disorder (OCD), hoarding, trichotillomania, eating disorders, Generalized Anxiety Disorder (GAD), adjustment disorders, panic disorder, major depressive episode, bipolar disorder in the nature of manic and depressive episodes, dysthymia, cyclothymia, psychotic disorders, schizophrenia; pharmaceutical preparations for the treatment of cerebellar disorders; pharmaceutical preparations for the treatment of cerebellar disorders, namely, spinocerebellar ataxia, Friedriech's ataxia, multisystem atrophy, essential tremor; pharmaceutical preparations for the treatment of hearing disorders, tinnitus, delirium, sleep disorders, parasomnias, learning disorders, Attention Deficit Disorder (ADD), Pervasive Developmental Disorders (PDD), Asperger's syndrome, autism, menopausal hot flashes; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of cancer, namely, monotherapy and adjunctive use
Classification Information
International Class
005 - Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. - Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes
006, 018, 044, 046, 051, 052
Class Status Code
6 - Active
Class Status Date
2018-01-04
Primary Code
005
Correspondences
Name
Monica Riva Talley
Address
Please log in with your Justia account to see this address.
Trademark Events
Event DateEvent Description
2017-12-21NEW APPLICATION ENTERED IN TRAM
2018-01-04NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
2018-03-27ASSIGNED TO EXAMINER
2018-03-29NON-FINAL ACTION WRITTEN
2018-03-29NON-FINAL ACTION E-MAILED
2018-03-29NOTIFICATION OF NON-FINAL ACTION E-MAILED
2018-08-30TEAS RESPONSE TO OFFICE ACTION RECEIVED
2018-08-30CORRESPONDENCE RECEIVED IN LAW OFFICE
2018-08-31TEAS/EMAIL CORRESPONDENCE ENTERED
2018-09-06APPROVED FOR PUB - PRINCIPAL REGISTER
2018-09-21ASSIGNED TO LIE
2018-10-10NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
2018-10-30PUBLISHED FOR OPPOSITION
2018-10-30OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
2018-12-25NOA E-MAILED - SOU REQUIRED FROM APPLICANT
2019-06-03TEAS EXTENSION RECEIVED
2019-06-03EXTENSION 1 FILED
2019-06-03EXTENSION 1 GRANTED
2019-06-05NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
2019-10-23TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
2019-10-23ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
2019-12-19TEAS EXTENSION RECEIVED
2019-12-19EXTENSION 2 FILED
2019-12-19EXTENSION 2 GRANTED
2019-12-21NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
2020-01-13TEAS WITHDRAWAL OF ATTORNEY RECEIVED
2020-01-13WITHDRAWAL OF ATTORNEY GRANTED
2020-02-03TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
2020-02-03ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
2020-06-17TEAS EXTENSION RECEIVED
2020-06-30CASE ASSIGNED TO INTENT TO USE PARALEGAL
2020-06-17EXTENSION 3 FILED
2020-06-30EXTENSION 3 GRANTED
2020-07-01NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
2020-12-21TEAS EXTENSION RECEIVED
2020-12-21EXTENSION 4 FILED
2020-12-21EXTENSION 4 GRANTED
2020-12-23NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
2021-06-21TEAS EXTENSION RECEIVED
2021-06-21EXTENSION 5 FILED
2021-06-23EXTENSION 5 GRANTED
2021-06-24NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
2022-01-31ABANDONMENT - NO USE STATEMENT FILED
2022-01-31ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED